Burnside-Butler Syndrome: Signs, Causes, and Diagnosis

Burnside-Butler syndrome is a genetic condition caused by a tiny missing segment on chromosome 15, and it is now recognized as one of the most common disease-associated copy number variations found in humans.¹ The deletion sits in a region called 15q11.2 between two breakpoints labeled BP1 and BP2, removing four genes that play roles in brain development. Despite being relatively common, the syndrome has a wide range of outcomes: some carriers have significant developmental and behavioral challenges, while others seem largely unaffected, which has made it both clinically important and surprisingly tricky to pin down.

What Gets Deleted and Why It Matters

The long arm of chromosome 15 is unusually rich in repeated DNA sequences called segmental duplications. These repeats mark five breakpoints (BP1 through BP5) along the chromosome, and they make the region prone to rearrangements during cell division.² When the DNA between BP1 and BP2 gets lost, roughly 500 kilobases of genetic material disappear. That stretch contains four protein-coding genes: NIPA1, NIPA2, CYFIP1, and TUBGCP5. All four are active in the brain and are involved in how nerve cells grow, connect, and communicate.³

Each gene has its own known disease associations. NIPA1 mutations are linked to a form of hereditary spastic paraplegia. NIPA2 is connected to Angelman syndrome and Prader-Willi syndrome. CYFIP1 is tied to Fragile X syndrome and autism. TUBGCP5 has associations with Prader-Willi syndrome as well.¹ When all four are deleted together, the result is a broad neurodevelopmental picture rather than any single clear-cut condition. This is partly why the syndrome took a long time to be recognized as a distinct entity: it doesn’t produce one signature feature, but rather a constellation of overlapping issues.

The Most Common Signs

Burnside-Butler syndrome shows up primarily through developmental and behavioral features, though the severity varies enormously from one person to the next. In a review of reported cases, developmental delay of some kind was present in about three-quarters of affected individuals. Language impairment was nearly as common, appearing in roughly two-thirds of cases. Motor delay was documented in about two in five people with the deletion.⁴

Behavioral and psychiatric features are also prominent. Attention deficit disorder or ADHD is reported in about a third of carriers, and autism spectrum disorder in just over a quarter. Seizures or epilepsy occur in a similar proportion. Schizophrenia and paranoid psychosis have been reported in roughly a fifth of cases, though this figure comes from clinically ascertained groups, meaning people who came to medical attention because they already had problems, and the true rate in all carriers is probably lower.⁵

Beyond the neurological and behavioral features, some affected individuals show physical findings. Craniofacial differences, orthopedic issues related to connective tissue, abnormal reflexes, and coordination problems have been reported across families with the deletion.⁶ Congenital heart defects have also been noted in a number of cases. However, no single physical feature or facial pattern is distinctive enough on its own to point a clinician toward the diagnosis just by looking at a child. The absence of a clear “gestalt” is one reason the syndrome is often identified only after genetic testing is done for other reasons.

Why the Same Deletion Can Look So Different

One of the most confusing aspects of Burnside-Butler syndrome is its variable expressivity and incomplete penetrance. In plain terms, some people who carry the deletion have serious challenges, while others carry it and function well enough that they never seek medical attention. Parents who carry the deletion themselves sometimes learn about it only after their child is diagnosed. This variability is a major reason the deletion was historically classified as a “variant of uncertain significance” by some labs, though increasing evidence now supports its role as a genuine risk factor for neurodevelopmental problems.

Several factors may contribute to how the deletion plays out in any given individual. The rest of a person’s genome matters. A detailed study of five families found that affected children often carried additional variants in genes associated with autism spectrum disorder, averaging about six such variants per child on top of the 15q11.2 deletion.⁶ This “second hit” model suggests the BP1-BP2 deletion alone may not always be enough to cause obvious symptoms, but it lowers the threshold so that additional genetic or environmental factors can push a person into clinical territory.

Parent-of-Origin Effects

An intriguing finding in Burnside-Butler syndrome is that the parent who passes down the deletion seems to influence which features a child develops. When the deletion is inherited from the mother, carriers are more likely to present with a larger-than-average head circumference, epilepsy, and autism spectrum disorder. When the deletion comes from the father, congenital heart disease and abnormal muscular features are more common instead.⁷

This pattern held up even after researchers excluded sibling sets and individuals who carried additional genetic variants of uncertain significance, which strengthens the case that the parent-of-origin effect is real and not just a statistical artifact. The finding is consistent with the broader biology of chromosome 15q, which is famously home to imprinted genes where the maternal and paternal copies are expressed differently. Prader-Willi syndrome and Angelman syndrome, two better-known conditions involving larger deletions further along the same chromosome arm, are themselves classic examples of imprinting disorders. The BP1-BP2 region sits nearby, and its genes appear to be influenced by similar mechanisms.

What Brain Imaging Shows

Researchers have used large-scale brain imaging datasets to see whether the 15q11.2 BP1-BP2 deletion leaves visible marks on the brain, and the answer is yes. In a study comparing deletion carriers with noncarriers, those with the deletion had significantly lower total brain surface area, thicker cortices, and smaller volume in a structure called the nucleus accumbens.⁸ The nucleus accumbens plays a key role in motivation and reward processing, which may connect to some of the behavioral features seen in the syndrome.

These brain changes are subtle on an individual level. You wouldn’t necessarily spot them on a routine scan. But across large groups, the pattern is consistent and statistically clear, reinforcing the idea that losing these four genes has genuine biological consequences for how the brain is built, even in people whose day-to-day functioning may appear relatively normal.

How Burnside-Butler Syndrome Is Diagnosed

The deletion that causes Burnside-Butler syndrome is far too small to see on a standard chromosome test (a karyotype). It only spans about half a megabase of DNA. The tool that has made diagnosis possible is chromosomal microarray analysis, sometimes called CMA or simply “microarray.” This technology scans the genome at high resolution, detecting gains and losses of DNA that are invisible to older methods.⁹ In many countries, CMA is now the recommended first-line genetic test for children with unexplained developmental delay, intellectual disability, or autism spectrum disorder.

A thorough family history remains important. Because the deletion is frequently inherited rather than occurring spontaneously, testing the parents of an affected child often reveals that one of them carries the same deletion, sometimes with mild or no symptoms. Knowing which parent carries the deletion provides useful information, both for understanding the child’s likely clinical trajectory based on the parent-of-origin effects described above and for counseling the family about the chance of the deletion appearing in future pregnancies.

One real-world challenge is interpretation. When a microarray flags a BP1-BP2 deletion, some laboratories still report it as a “variant of uncertain significance” rather than labeling it as definitively pathogenic. The evidence base has grown substantially over the past decade, and many genetics groups now consider the deletion to be a recognized susceptibility factor for neurodevelopmental disorders. But in practice, families sometimes receive ambiguous results that leave them uncertain about what the finding means for their child.

Overlap with Prader-Willi Syndrome and Angelman Syndrome

Burnside-Butler syndrome occupies a stretch of chromosome 15 that sits just upstream of the larger deletions responsible for Prader-Willi syndrome and Angelman syndrome. When clinicians discuss these bigger deletions, they distinguish between two types. A Type I deletion extends from BP1 to BP3 and includes the four genes lost in Burnside-Butler syndrome. A Type II deletion extends from BP2 to BP3, sparing those four genes. People with Prader-Willi syndrome who carry the larger Type I deletion tend to be more severely affected than those with the smaller Type II deletion, suggesting that the loss of the BP1-BP2 genes makes a measurable difference even in the context of a much bigger genetic event.¹⁰

This connection is useful for understanding why the BP1-BP2 region matters. If losing these four genes worsens the clinical picture even in people who are already missing a much larger set of genes, it reinforces the idea that the BP1-BP2 deletion on its own, as in Burnside-Butler syndrome, is biologically meaningful and not just a benign polymorphism that happens to sit near more important genes.

The Microduplication Side of the Coin

The same segmental duplications that predispose the BP1-BP2 region to deletions also predispose it to duplications, where an extra copy of the region is gained instead of lost.¹¹ Carriers of the microduplication can also experience developmental and language delay, though the clinical picture is generally considered milder and less well-defined than the deletion syndrome.

An interesting finding from psychiatric genetics is that the duplication, rather than the deletion, has been linked to anorexia nervosa. In a study comparing over a thousand patients with anorexia to more than seven thousand controls, the microduplication at 15q11.2 BP1-BP2 was significantly enriched in the anorexia group, while the microdeletion showed no such association.¹² This is a useful reminder that gains and losses of the same genetic material don’t simply produce mirror-image effects. The biology is more nuanced, with different dosages of these genes potentially nudging different brain circuits in different directions.

Genetic Counseling and Prenatal Considerations

Families who learn about the BP1-BP2 deletion face a genuinely difficult counseling situation. The deletion is inherited in about half of identified cases, which means it follows a pattern where each pregnancy from a carrier parent has a 50 percent chance of inheriting the deletion. But because the outcomes are so variable, knowing a fetus carries the deletion doesn’t tell you how severely, if at all, the child will be affected.

Prenatal diagnosis is technically straightforward. Microarray testing on chorionic villus sampling or amniocentesis specimens can detect the deletion reliably. A case report of a Chinese family illustrated this directly: a paternally inherited 15q11.2 microdeletion was identified prenatally and confirmed as a known pathogenic factor for neurodevelopmental issues and congenital heart disease.¹³ The challenge isn’t detecting the deletion; it’s advising the family on what it means. Genetic counselors typically emphasize the range of possible outcomes, the influence of parent-of-origin, and the current limits of prediction.

For families already raising a child with Burnside-Butler syndrome, there is no specific medical treatment for the underlying deletion. Management is symptom-based: speech therapy for language delays, occupational therapy for motor issues, behavioral interventions for ADHD or autism-related challenges, and standard medical care for associated conditions like epilepsy or heart defects. Early intervention services, ideally beginning before school age, are generally recommended because the most common features of the syndrome, particularly speech and motor delays, are areas where early support tends to make the biggest practical difference.

Why the Syndrome Is Probably Underdiagnosed

Despite being described as one of the most frequent pathogenic copy number variations in humans, Burnside-Butler syndrome remains poorly recognized outside of genetics clinics. Several factors converge to keep it under the radar. The deletion is invisible on standard chromosome tests, so it can only be found with microarray or similar high-resolution genomic testing. Many children with mild developmental delays never receive genetic testing at all. And when the deletion is found, laboratories sometimes hedge on its significance, leaving families and their doctors uncertain about whether the result explains the child’s difficulties.

Population studies of large biobank datasets have shown that the deletion exists in roughly 0.5 to 1 percent of the general population, depending on the cohort. Most of those carriers were never diagnosed with anything. This creates a chicken-and-egg problem for research: the deletion is common enough that it clearly doesn’t guarantee disability, but it reliably shows up at higher rates in groups with neurodevelopmental or psychiatric diagnoses than in the general population. The scientific consensus has been moving toward treating it as a genuine risk factor with variable penetrance rather than either dismissing it as benign or labeling it as a guaranteed cause of disease.

For parents and clinicians, the practical takeaway is that the deletion’s presence should prompt monitoring and early support rather than alarm. A child found to carry the BP1-BP2 deletion benefits from developmental surveillance, speech and language screening, and attention to behavioral milestones. Detailed family history can sometimes reveal a pattern of mild learning or attention issues across generations that, in retrospect, map onto the deletion’s known associations. In that context, the diagnosis can be genuinely clarifying, putting a name to what a family may have noticed for years without understanding the biological thread connecting it.